Establishment of NAFLD Cohort and Development of Fibrosis Markers
ConditionFibrosis of Liver
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSeoul National University Boramae Hospital
About this trial
This study is designed for establishment of non-alcoholic fatty liver disease patients cohort to development of markers to predict histologic progression of liver fibrosis.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with histologically confirmed fatty liver disease
Patients with radiologically confirmed fatty liver disease
Disqualifiers
History of significant alcohol consumption
Viral hepatitis
Autoimmune hepatitis
Metabolic diseases (e.g. hemochromatosis, M. Wilson, alpha 1-antitrypsin deficiency)
Trial population
Non-alcoholic fatty liver disease
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Liver biopsy
Procedure/SurgeryPercutaneously liver biopsy will be performed for evaluate steatosis and fibrosis.
ARFI
DeviceAcoustic radiation force impulse (ARFI) imaging will be performed for evaluate fibrosis of liver.
SWE
DeviceSupersonic shear wave elastography (SWE) will be performed for evaluate fibrosis of liver.
Transient elastography
DeviceTransient elastography will be performed for evaluate fibrosis of liver.
Treatment groups
1,000 Participants
are divided into 1 treatment groupGroup A: NAFLD4 interventions
Trial outcomes
Primary outcomes
1
histologic steatosis and fibrosis grade
We will evaluate fibrosis using laboratory examination, radiologic evaluation and liver tissue pathology.
Time frame
baselineSecondary outcomes
1
Development of markers for hepatic fibrosis progression
We will analysis and development fibrosis markers by obtained blood sample and liver tissue,
Time frame
baseline and every 6 months (up to 1year)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov